Fabio Carbone, Colorectal Surgeon at IRCCS National Cancer Institute G. Pascale Foundation, Naples, Italy, shared a post on LinkedIn:
“New publication in the Journal of Gastrointestinal Surgery
The ERECS trial, an Italian multicentre study exploring early recurrence after esophagectomy for esophagogastric junction adenocarcinoma, has just been published.
Key findings (594 patients, 7 high-volume centres):
- Recurrence remains frequent (41%), with around 1 in 4 patients recurring within 12 months
- Early recurrence has a major prognostic impact (1-year OS 40% vs 70% in late recurrence)
- Several factors help identify patients at higher risk:
- Advanced pathological stage
- Poor response to neoadjuvant treatment (Mandard classification)
- Lower BMI, possibly reflecting biological frailty
Take-home message: early identification of high-risk patients may support more personalised treatment strategies and follow-up pathways.
I am pleased to have collaborated on the ERECS trial together with all colleagues involved.”
Title: Early Recurrence of Esophagogastric junction adenoCarcinoma after Surgery: a multicentre analysis of risk factors (ERECS Trial)
Authors: Stefano de Pascale, Riccardo Rosati, Vincenzo Bagnardi, Andrea Cossu, Giovanni Ferrari, Samuele Frassoni, Simone Giacopuzzi, Monica Gualtierotti, Lucia Moletta, Mario Morino, Giovanni Pallabazzer, Marco Realis Luc, Fabrizio Rebecchi, Stefano Santi, Michele Valmasoni, Jacopo Weindelmayer, Uberto Fumagalli Romario
Read the Full Article.
More posts on Colorectal Cancer on OncoDaily.